February 24, 2020
Teva Pharmaceuticals USA is recalling two lots of extended-release methylphenidate hydrochloride tablets because product bottles may not contain desiccants, according to the February 19, 2020, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects the following products, which were distributed throughout the United States:
- methylphenidate hydrochloride extended-release tablets, 18 mg, 100-count bottles (NDC 62037-725-01) from lot 1332796 A (Exp. 11/20), and
- methylphenidate hydrochloride extended-release tablets, 27 mg, 100-count bottles (NDC 62037-734-01) from lot 1332799A (Exp. 11/20).
Teva Pharmaceuticals voluntarily initiated the recall January 27, 2020. The FDA designated the recall Class II on February 10, 2020. Use of a drug under a Class II recall could cause temporary or medically reversible adverse health consequences, or a remote possibility of serious harm.
Methylphenidate is a prescription stimulant used to treat attention-deficit/hyperactivity disorder as well as narcolepsy.